| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18383 R77505 |
Heuvelman, 2023 | Autism spectrum disorder - Validated Read code list among primary care clinical and referral records - Mean age at end of follow-up 10.04 years, range 4–22 years | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: no or not specified Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) | 1.37 [0.88;2.14] | -/2,088 -/16,330 | - | 2,088 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18249 R76860 |
Suarez (Controls unexposed, discontinuers), 2022 | Autism Spectrum Disorder - ≥ 2 dates with ICD-9 Dx 299.xx (except 299.1x) - At ≥ 1 year of age | 2nd and/or 3rd trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: no or not specified Unexposed sick: recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy) | 1.11 [0.82;1.49] | 324/55,722 66/11,529 | 390 | 55,722 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18250 R76861 |
Suarez (Controls unexposed, general pop), 2022 | Autism Spectrum Disorder - ≥ 2 dates with ICD-9 Dx 299.xx (except 299.1x) - At ≥ 1 year of age | 2nd and/or 3rd trimester | retrospective cohort (claims database) | unexposed (general population or NOS) excluded | Adjustment: Yes Monotherapy: no or not specified |
0.99 [0.88;1.13] excluded (control group) |
324/55,788 11,437/2,996,295 | 11,761 | 55,788 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S10011 R46820 |
Ames, 2021 | Autism spectrum disorder (ASD): diagnostic criteria on the Autism Diagnostic Observation Schedule and the full ASD diagnostic criteria on the ADI-R or one of three alternative criteria on the ADI-R (age NOS). | 3 months (or more) before pregnancy or during pregnancy excluded | case control | unexposed, disease free | Adjustment: No Monotherapy: no or not specified |
1.52 [0.99;2.32] C excluded (exposition period) |
49/89 1,318/2,949 | 1,367 | 89 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6549 R46822 |
Brown, 2017 | Autism spectrum disorder (ASD) Diagnostic (ICD-9/OHIP: 299; ICD-10: F84) - Age: 4-10 years (mean: 4.95 years) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: no or not specified | 2.39 [0.56;9.82] | -/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11339 R46823 |
Rai (Controls exposed to TCA), 2017 | Autism spectrum disorder (ICD-9 (299), ICD-10 (F84), or DSM-IV (299) codes) - At 4-17 years | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No Monotherapy: no or not specified |
0.48 [0.26;0.90] C excluded (control group) |
31/912 16/235 | 47 | 912 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7484 R46824 |
Rai (Controls unexposed, disease free), 2017 | Autism spectrum disorder (ICD-9 (299), ICD-10 (F84), or DSM-IV (299) codes) at 4-17 years | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No Monotherapy: no or not specified |
1.68 [1.18;2.41] C excluded (control group) |
31/912 4,889/238,943 | 4,920 | 912 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7828 R46825 |
Rai (Controls unexposed, sick), 2017 | Autism spectrum disorder (ICD-9 (299), ICD-10 (F84), or DSM-IV (299) codes) at 4-17 years | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: Yes Monotherapy: no or not specified Unexposed sick: old history of illness/treatment (> 12 months before pregnancy) or not specified | 1.45 [0.98;2.16] | 31/912 353/12,325 | 384 | 912 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7636 R46826 |
Viktorin (Controls unexposed, NOS), 2017 | Autism spectrum disorder (ICD10- F84.0, F84.1, F84.2, F84.3, F84.4, F84.5, F84.8, or F84.9) at 7-8 years | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: Yes Monotherapy: no or not specified |
1.35 [0.87;2.08] excluded (control group) |
22/1,016 1,524/172,646 | 1,546 | 1,016 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7819 R46827 |
Viktorin (Controls unexposed, sick), 2017 | Autism spectrum disorder (ICD10- F84.0, F84.1, F84.2, F84.3, F84.4, F84.5, F84.8, or F84.9) at 7-8 years | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes Monotherapy: no or not specified Unexposed sick: old history of illness/treatment (> 12 months before pregnancy) or not specified | 1.17 [0.71;1.95] | 16/672 -/- | - | 672 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7864 R46821 |
Bérard, 2016 | Autism spectrum disorder (ICD-9 codes 299.0, 299.8, 299.9; ICD-10 codes F84.0, F84.1, F84.5, F84.8, F84.9) - Age : 0-11 years (mean: 4.0) | 2nd and/or 3rd trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 0.45 [0.05;4.26] | 1/292 1,004/142,716 | 1,005 | 292 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 6 studies | 1.25 [1.03;1.51] | 1,779 | 59,686 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, discontinuers; 2: Controls unexposed, sick; 3: Controls unexposed, sick;
Asymetry test p-value = 0.8922 (by Egger's regression)
slope=0.1982 (0.1768); intercept=0.1067 (0.7389); t=0.1444; p=0.8922
excluded 11339, 7484, 7636, 18250